Damian Garde joins Allison, Adam, and Elaine to discuss his article about Boris Nikolic, a well-connected biotech investor ...
Stocktwits on MSN
SLS stock rallies ahead of AML trial readout — 'Pharma Bro' Martin Shkreli says he's still 'very bearish,' predicts drug will fail
The debate centers on Sellas’ Phase 3 Regal trial, which is testing its immunotherapy Galinpepimut-S (GPS) as a maintenance treatment for AML patients. ・The readout is nearing a key trigger, with ...
Spyre Therapeutics CEO Cameron Turtle talks about the search for an IBD treatment on this week's "The Readout LOUD." ...
Asianet Newsable on MSN
SLS stock falls premarket: CEO touts GPS leukemia strategy, but investors stay cautious as AML trial nears readout
The CEO said Sellas is pursuing a “security force” immunotherapy strategy that trains immune cells to recognize cancer even as tumors evolve.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results